Loading ...
PAC therapyUS804141819 Dec 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Apr 200711 Oct 2007Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Ischemia detection using a heart sound sensorUS804141819 Dec 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
verificationUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
predictionUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
sensorUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
2014Ecole Polytechnique Federale De LausanneMicrofabricated neurostimulation deviceUS20070239230 * Apr 27 , 2007Oct 11 , 2007Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
devicesUS20060136006 * Dec 19 , 2005Jun 22 , 2006Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Oct 2007 Medtronic , Inc. System and method for regulating cardiactriggeredtherapy
Oct 2011 Medtronic , Inc. System and method for regulating cardiactriggeredtherapy
Oct 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS804141819 Dec 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
major advances ... important factorswill ... influencetherapy
Mar 21 , 2008Oct 11 , 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
System for the detection of cardiac eventsUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Aug 17 , 2000Mar 1 , 2001Impulse Dynamics NvApparatus and method for determining a mechanical property of an organ or body cavity by impedance determinationWO2006066098A1Dec 19 , 2005Jun 22 , 2006Medtronic IncSystem and method for monitoring or treating nervous system disordersWO2006066099A1Dec 19 , 2005Jun 22 , 2006Medtronic IncSystem and method for regulating cardiopulmonary triggered therapy to the brainWO2006066280A1Dec 19 , 2005Jun 22 , 2006Medtronic IncSystem and method for monitoring or treating nervous system disordersWO2006086075A1Dec 19 , 2005Aug 17 , 2006Medtronic IncSystem and method for regulating cardiactriggeredtherapy
Oct 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418 * 19 Dec 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Oct 2011Medtronic , Inc . Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedureUS804141819 Dec 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Sep 2011The Invention Science Fund I , LlcLumen - traveling biological interface device and method of useUS804141819 Dec 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Device and method for automatic threshold settingUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Method and system for treatment of neurocardiogenic syncopeUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Multi - functional burr hole assemblyUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Controlling pressure in adjustable restriction devicesUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Ingestible therapy activator system and methodUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
active housing subcutaneous positioning methodsUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Electric modulation of sympathetic nervous systemUS8036736Oct 11 , 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Oct 18 , 2011 Medtronic , Inc. System and method for regulating cardiactriggeredtherapy
Sensitivity analysis for selecting therapy parameter setsUS8036736Oct 11 , 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Sensitivity analysis for selecting therapy parameter setsUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
System for evaluating performance of an implantable medical deviceUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Spatial temporal deep brain stimulation methods and systemsUS8036736Oct 11 , 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
to affect people(passive) is designedTherapy
SPG stimulation for treating complications of subarachnoid hemorrhageUS8036736Mar 21 , 2008Oct 11 , 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Sensitivity analysis for selecting therapy parameter setsUS8036736Mar 21 , 2008Oct 11 , 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Automated optimization of multi - electrode pacing for cardiac resynchronizationUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Vehicle diagnostic or prognostic message transmission systems and methodsUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
Oct 2011Neuro Vista CorporationImplantable systems and methods for identifying a contra - ictal condition in a subjectUS804141819 Dic 200518 Oct 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
to combat these factors(passive) is designedIntralipid therapy
Use of motion sensor for dynamic updating of heart detection thresholdUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
System and method for frequency synchronization in a wireless non - hierarchical networkUS8041418Dec 19 , 2005Oct 18 , 2011Medtronic , Inc . System and method for regulating cardiactriggeredtherapy
alsopreventsalso
the development of diabetes ... but other explanations , such as the anti - inflammatory properties of this drug in combination with its endothelial effects , can not be excluded with these analyses . " , keywords =may ... influencethe development of diabetes ... but other explanations , such as the anti - inflammatory properties of this drug in combination with its endothelial effects , can not be excluded with these analyses . " , keywords =
or decrease bleeding episodesto preventor decrease bleeding episodes
bleeding ... ( warfarin or aspirinmay causebleeding ... ( warfarin or aspirin
to restore the health of the tooth and avoid the need for an extractiondesignedto restore the health of the tooth and avoid the need for an extraction
the complications that accompany the loss of a tooth : bite changes , jaw joint problems , difficulty chewing and adjacent tooth supportpreventsthe complications that accompany the loss of a tooth : bite changes , jaw joint problems , difficulty chewing and adjacent tooth support
to partial recovery from spinal cord injury in rats 3Stem cell therapyleadsto partial recovery from spinal cord injury in rats 3Stem cell therapy
or binary options brokers ranking bleeding episodesto preventor binary options brokers ranking bleeding episodes
in clinical improvement but no eradication after 10 months of follow - upresultedin clinical improvement but no eradication after 10 months of follow - up
to partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in ratsleadsto partial recovery from spinal cord injury in rats 2Combination therapy leads to partial recovery from spinal cord injury in rats
in patients with Paget ’s diseaseresultsin patients with Paget ’s disease
loss of CSF3R mutated clone , cell size normalizationcausesloss of CSF3R mutated clone , cell size normalization
stroke in patients with atrial fibrillationto preventstroke in patients with atrial fibrillation
the infection from spreading into the bone which could lead to pain and tooth losspreventsthe infection from spreading into the bone which could lead to pain and tooth loss
to a marked increase in serum CA-125 levels in all patients with mesothelioma treated at our institutionledto a marked increase in serum CA-125 levels in all patients with mesothelioma treated at our institution
a rupture in some patients with pulmonary hydatid diseasecan causea rupture in some patients with pulmonary hydatid disease
to a significant reduction in mean LDL cholesterol level in patients with type 2 diabetesledto a significant reduction in mean LDL cholesterol level in patients with type 2 diabetes
renal functional decline in untreated dyslipidemia patientspreventedrenal functional decline in untreated dyslipidemia patients
the loss of vertebral and trochanteric bone in corticosteroid - treated patientspreventsthe loss of vertebral and trochanteric bone in corticosteroid - treated patients
one major CHD event ( CHD death or nonfatal myocardial infarction ... in 23 patients with IFG and 18 patients with diabetespreventedone major CHD event ( CHD death or nonfatal myocardial infarction ... in 23 patients with IFG and 18 patients with diabetes
to the reduction of number of new cases of AF after CABG in patients with IHDcontributedto the reduction of number of new cases of AF after CABG in patients with IHD
in greater than two - fold increase in CD31 + LOEPCs versus untreated animalsresultedin greater than two - fold increase in CD31 + LOEPCs versus untreated animals
increase the CAT activity without any effect on the activities of GSH - Px and SODcausedincrease the CAT activity without any effect on the activities of GSH - Px and SOD
a 13 % reduction from baseline triglycerides stages and an 8 % increase from baseline HDL - C amountscreateda 13 % reduction from baseline triglycerides stages and an 8 % increase from baseline HDL - C amounts
art , fatigue , insomnia , mild depression , relaxation , the blues Previous Post Artless but Reading Next Postcreatingart , fatigue , insomnia , mild depression , relaxation , the blues Previous Post Artless but Reading Next Post
to normalization of platelet counts in 89 % of treated patients ... along with a reduction in the TMA intervention rateledto normalization of platelet counts in 89 % of treated patients ... along with a reduction in the TMA intervention rate
in complete or partial response in 4 ( 36.3 % ) of 11 and 7 ( 63.7 %resultedin complete or partial response in 4 ( 36.3 % ) of 11 and 7 ( 63.7 %
to significant improvements in efficacy outcomes in patients with steroid - refractory acute graft - versus - host diseaseledto significant improvements in efficacy outcomes in patients with steroid - refractory acute graft - versus - host disease
a decrease in transient lower esophageal sphincter ( LES ) relaxations and an increase in gastric yield pressure ... and therefore reduces refluxcausesa decrease in transient lower esophageal sphincter ( LES ) relaxations and an increase in gastric yield pressure ... and therefore reduces reflux
in less common development with LEAD trial subjects showing an average 8.6 % of patients developing antidrugresultedin less common development with LEAD trial subjects showing an average 8.6 % of patients developing antidrug
recurrent AF in sympto- ( 3 ) Intravenous beta blockers and nondihydropyridine matic patients with little or no LA enlargementto preventrecurrent AF in sympto- ( 3 ) Intravenous beta blockers and nondihydropyridine matic patients with little or no LA enlargement
in a reduction in body mass , an improvement in insulin resistance , and a decrease in abdominal circumference , key predictors of diabetes in humansresultedin a reduction in body mass , an improvement in insulin resistance , and a decrease in abdominal circumference , key predictors of diabetes in humans
in a discount in physique mass , an improvement in insulin resistance , and a decrease in abdominal circumference , key predictors of diabetes in peopleresultedin a discount in physique mass , an improvement in insulin resistance , and a decrease in abdominal circumference , key predictors of diabetes in people
to an improvement of cognitive and non - cognitive symptoms in patients with dementia and mild cognitive impairment ... or even decelerate the course of declinecan leadto an improvement of cognitive and non - cognitive symptoms in patients with dementia and mild cognitive impairment ... or even decelerate the course of decline
HFD induce insulin resistance and oxidative stress thus leading to improved glycemic control , correction of dyslipidemia , better control of blood pressure and reasonably improved kidney function testpreventedHFD induce insulin resistance and oxidative stress thus leading to improved glycemic control , correction of dyslipidemia , better control of blood pressure and reasonably improved kidney function test
to complete resolutioncan leadto complete resolution
in a longer 3-year PFS compared to ipilimumab ( 31 % vs. 14 %resultedin a longer 3-year PFS compared to ipilimumab ( 31 % vs. 14 %
respiratory depression ( dose - dependentcan provokerespiratory depression ( dose - dependent
to prompt rejection reversalledto prompt rejection reversal
in a 30 % reduction in the hazard of developing DMresultedin a 30 % reduction in the hazard of developing DM